A recent study has suggested that there is an association between pain and neurocognitive dysfunction. 8 Specifically, patients with generalized pain and neuropathic pain, but not localized pain, fail certain cognitive tests more easily. 8 Therefore, it is important to establish a preclinical model to investigate the effects of pain on cognitive function and the underlying mechanisms.
It has been reported that neuroinflammation, including elevation of the levels of proinflammatory cytokine, may lead to cognitive dysfunction (reviewed in). 9 Specifically, proinflammatory cytokine interlukin-6 (IL-6) has been shown to be associated with cognitive dysfunction and mild cognitive impairment in medical and surgical patients. 10 IL-6 has also been shown to be involved in learning and memory function in rodents. [11] [12] [13] [14] [15] [16] Postsynaptic density 95 (PSD-95) is a postsynaptic marker. 17, 18 The decreases in PSD-95 levels are associated with a reduction in synapse number or synaptic loss and impairment of learning and memory. 16, [19] [20] [21] [22] The effects of pain on the levels of IL-6 and PSD-95 in brain tissues of mice, however, have not been assessed.
Finally, the context and tone test of the Fear Conditioning System (FCS) can be used to assess hippocampus-dependent and hippocampus-independent learning and memory, respectively. [23] [24] [25] [26] Our previous studies have shown that sleep disturbance can induce neuroinflammation and decrease the freezing time in the context test, but not tone test, of the FCS, which suggests that sleep disturbance may selectively induce neuroinflammation in the hippocampus and induce hippocampus-dependent learning and memory impairment in mice. 14 However, whether pain can cause hippocampusindependent or hippocampus-dependent changes in neurochemistry and neurobehavioral function remains unknown.
BACKGROUND: Pain might be associated with cognitive impairment in humans. However, the characterization of such effects in a preclinical model and the investigation of the underlying mechanisms remain largely to be determined. We therefore sought to establish a system to determine the effect of pain on cognitive function in mice. METHODS: Complete Freund's adjuvant (CFA) was injected in the hindpaw of 5-to 8-month-old wildtype and interleukin-6 knockout mice. Learning and memory function, and the levels of interleukin-6 and postsynaptic density (PSD)-95 in the cortex and hippocampus of mice were assessed. RESULTS: We found that the CFA injection-induced pain in the mice at 3 and 7 days after injection and decreased the freezing time (30.1 [16.5] vs 56.8 [28.1] seconds, P = 0.023) in the tone test, which assesses the hippocampus-independent learning and memory function, but not in a context test of Fear Conditioning System (15.8 [6.7] vs 18.6 [8.8] seconds, P = 0.622), which assesses the hippocampus-dependent learning and memory function, at 3 days after injection. Consistently, the CFA injection increased interleukin-6 (248% [11.6] vs 100% [7.9] , P < 0.0001) and decreased the PSD-95 (40% [10.0] vs 100% [20.3] , P < 0.0001) level in the cortex, but not hippocampus (95% [8.6] vs 100% [9.3] , P = 0.634), in the mice. The CFA injection induced neither reduction in the cortex PSD-95 levels nor cognitive impairment in the interleukin-6 knockout mice. CONCLUSIONS: These results suggest that pain induced by CFA injection might increase interleukin-6 levels and decrease PSD-95 levels in the cortex, but not hippocampus of mice, leading to hippocampus-independent cognitive impairment in mice. These findings call for further investigation to determine the role of pain in cognitive function. (Anesth Analg 2014;119:471-80) 
ANesthesiA & ANAlgesiA
We established a preclinical system in mice to assess whether pain could induce hippocampus-dependent (assessing by context test of FCS) or hippocampus-independent (assessing by tone test of FCS) learning and memory impairment in mice and alter the levels of IL-6 and PSD-95 in the cortex or hippocampus of mice.
METHODS Animals
The animal protocol was approved by the Standing Committee on Animals at Massachusetts General Hospital, Boston, MA. Wild-type (WT) C57BL/6J (The Jackson Laboratory, Bar Harbor, ME) and IL-6 knockout (KO) mice (B6.129S2-Il6tm1Kopf/J, the same genetic background C57BL/6J) (5-8 months old, The Jackson Laboratory) were randomly assigned to a complete Freund's adjuvant (CFA) injection or control group. A previous study has shown that the pain threshold in IL-6 KO mice is similar to that in WT mice. 27 Mice were housed in a controlled environment (20°C-22°C; 12-hour light: dark on a reversed light cycle) for 1 week before the studies. The maintenance and handling of mice were consistent with the guidelines of the National Institute of Health, and all efforts were made to minimize the number of animals studied.
Injection of Complete Freund's Adjuvant
Each mouse was briefly anesthetized with isoflurane (1.4% for 5 minutes). The mouse then received 20 μL CFA (Sigma, St. Louis, MO) or saline in the bottom of the right hindpaw as described in detail in a previous study. 28 CFA consists of heat-killed Mycobacterium tuberculosis in 85% paraffin oil and 15% mannide monoleate and is often used to induce pain (chemically induced) in rodents in pain research. 28 
Pain Threshold Test
Pain threshold was determined by using nylon von Frey filaments as described in a previous study. 29 Mice were placed on a wire mesh platform in clear cylindrical plastic enclosures 8-cm diameter and 10 cm in height. After 20 minutes on the platform, filaments were applied (bending force range from 0.008 to 26 gram; North Coast Medical, Inc., San Jose, CA) on the wound edge of the CFA-injected hindpaw for approximately 5 seconds with a 10-second interval between each stimulation. Withdrawal of the hindpaw from the floor was scored as a positive response. When no response was obtained, the next stiffer filament in the series was applied to the same paw. Each monofilament was applied to the hindpaw 5 times. The hindpaw withdrawal threshold (the pain threshold) was obtained as the force (in gram) at which foot withdrawal occurred for at least 3 of the 5 stimulations.
Fear Conditioning System
The FCS is a behavioral procedure designed to assess associative learning and memory. FCS has been often used to detect learning and memory impairment induced by anesthesia alone, anesthesia with surgery, and sleep disturbance. 14 We performed FCS studies as described in our previous studies and other studies. 30, 31 Specifically, the mice were exposed for training in the FCS (Stoelting Co., Wood Dale, IL) 24 hours after CFA injection. Each mouse was allowed to explore the chamber for 180 seconds before presentation of a 2-Hz pulsating tone (80 dB, 1500 Hz) that persisted for 60 seconds. The tone was followed immediately by a mild foot shock (0.8 mA for 0.5 seconds). Context (no tone period) and tone (tone period) learning and memory were probed 3, 7, and 14 days after the training in sequence. Mice in the same group were given the context test first and then a tone test 1 hour later. For the context test, each mouse (from either the control group or the CFA injection group) was allowed to stay in the chamber for 180 seconds, followed by another 180-second period without a tone, and finally 30 seconds for recovery. For the tone test, each mouse (from either the control group or the CFA injection group) was allowed to stay in the chamber for 180 seconds, followed by another 180-second period with a tone, and finally 30 seconds for recovery. Learning and memory were assessed by measuring the amount of time the mouse demonstrated "freezing behavior," defined as a completely immobile posture except for respiratory efforts, during the test period (the second 180-second period), which was analyzed by Any-Maze (Stoelting Co., Wood Dale, IL). The first 180-second period allowed mice to adjust to the environment before counting freezing time in the second 180-second period.
Brain Tissue Harvest and Protein Level Quantification
Different groups of mice from both the control condition and the pain condition were used for biochemistry studies. Three, 7, and 14 days after injection of CFA, mice were killed by decapitation (for Western blot analysis). The brain cortex (whole cerebral cortex) and hippocampus were harvested separately. Using a mouse brain map, the brain cortex and hippocampus were visually identified by the observers. For Western blot analysis, the harvested brain cortex or hippocampus was homogenized on ice using immunoprecipitation buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.5% Nonidet P-40) plus protease inhibitors (1 μg/mL aprotinin, 1 μg/mL leupeptin, 1 μg/mL pepstatin A). The lysates were collected, centrifuged at 12,000g for 10 minutes, and quantified for total proteins with a Bicinchoninic Acid protein assay kit (Pierce, Iselin, NJ).
Western Blot Analysis
IL-6 antibody (1:1000 dilution, Abcam, Cambridge, MA) was used to recognize IL-6 (24 kDa). PSD-95 antibody (1:1000, Cell Signaling, Danvers, MA) was used to detect PSD-95 (95 kDa). Antibody anti-β-Actin (1:10,000, Sigma, St. Louis, MO) was used to detect β-Actin (42 kDa). Western blot quantification was performed as described by Xie et al. 32 Briefly, signal intensity was analyzed using a Bio-Rad (Hercules, CA) image program (Quantity One). We quantified Western blots in 2 steps; first, we used β-Actin levels to normalize (e.g., determine the ratio of IL-6 to β-Actin amount) protein levels and control for loading differences in the total protein amount. Second, we presented protein level changes in mice in the CFA injection group as a percentage of those in the control group. One hundred percent of protein level changes refer to control levels for the purpose of comparison of experimental conditions.
Statistics
Data are expressed as mean and standard deviation (SD). The number of samples varied from 9 to 10. Samples were normally distributed (tested by Shapiro-Wilk test, data not shown). A 2-tailed Student t test (the Student t test with unequal variances or Welch's method) was used to compare differences in freezing time, IL-6 levels, and PSD-95 levels between the CFA injection and control groups. Mice at 3, 7, and 14 days after injection were separate groups of mice; thus, 1-way analysis of variance (ANOVA) was used to analyze the levels of IL-6 and PSD-95 between control group and the CFA injection group at 3, 7, and 14 days after injection. Post hoc analyses were performed if the main effect was found to be statistically significant. The respective P value was Bonferroni-adjusted by the number of comparisons made, 4 pairs for IL-6 levels and 4 pairs for PSD-95 levels. Specifically, we used multiple 2-group Student t tests with the P values Bonferroni correction to compare the difference in IL-6 and PSD-95 levels between the control and the CFA injection groups at 3, 7, or 14 days after injection. P values <0.05 (*) and 0.01 (**) were considered statistically significant. Significance testing was 2 tailed, and Prism 6 software (La Jolla, CA) was used to analyze the data.
RESULTS

CFA Injection-Induced Pain in Mice
We first established a preclinical system of producing pain in mice by injection of CFA into the right hindpaw. The injection of CFA reduced the pain threshold at 3 days after injection ( Fig. 1A) : 0.15 (0.11) vs 0.65 (0.19) g, P < 0.0001, and 7 days after injection ( Fig. 1B) : 0.16 (0.08) vs 0.61 (0.19) g, P < 0.0001. CFA injection also reduced the pain threshold at 14 days after injection; however, the difference did not reach significance ( Fig. 1C ): 0.42 (0.21) vs 0.64 (0.31) g, P = 0.077. These data showed that CFA injection in mice paws could cause pain, which demonstrated that we were able to establish a preclinical model of pain for the current experiments.
CFA Injection-Induced Pain Caused Transient Cognitive Impairment in Mice
Given that we established a preclinical model of pain, we asked whether CFA injection-induced pain in mice might cause cognitive impairment. We determined the effects of CFA injection-induced pain on the function of learning and memory in the FCS. Different groups of mice were used in the FCT studies at 3, 7, and 14 days after injection. FCS studies showed that CFA injection-induced pain ( Fig. 2A , black bar) led to decreases in freezing time in the FCS tone test as compared with the control condition ( Fig. 2A , white bar) at 3 days after injection: 30.1 (16.5) vs 56.8 (28.1) seconds, P = 0.023. Next, we found that CFA injection-induced pain did not decrease freezing time in the FCS context test ANesthesiA & ANAlgesiA compared with the control condition at 3 days after injection: black bar versus white bar, P = 0.622. (Fig. 2B ). We found that CFA injection-induced pain did not significantly change the freezing time in the FCS tone or context test compared with the control condition at 7 ( Fig. 2C , P = 0.299; Fig. 2D , P = 0.462) and 14 days ( Fig. 2E , P = 0.595; Fig. 2F , P = 0.367) after injection in the mice. These results suggest that the CFA injection-induced pain may induce a transient impairment of learning and memory function in mice at 3, but not 7 and 14, days after injection. Moreover, CFA injection-induced pain might selectively impair hippocampus-independent learning and memory function (detected by tone test in FCS) in mice.
CFA Injection-Induced Pain Caused Transient Increase in IL-6 Levels in the Cortex, But Not Hippocampus, of Mice
Given that IL-6 is associated with cognitive function in rodents [11] [12] [13] [14] [15] [16] and that CFA injection-induced pain caused cognitive impairment in the mice, we next asked whether CFA injection-induced pain could increase IL-6 levels in brain tissues of mice. Immunoblotting of IL-6 demonstrated that CFA injection-induced pain increased IL-6 levels in cortexes as compared with the control condition at 3, but not 7 and 14, days after injection (Fig. 3A) . There was no significant difference in brain β-Actin levels between the control condition and CFA injection condition (Fig. 3A) . Western blot quantification, based on the ratio of IL-6 to β-Actin, illustrated that there was a significant difference in IL-6 levels in the cortexes between the control condition and CFA injection condition at 3, 7, and 14, days after injection (Fig. 3B, 1 -way ANOVA, F = 339.4, P < 0.0001). Post hoc test showed that CFA injection-induced pain increased IL-6 levels in cortexes as compared with the control condition at 3 (248% [11.7] vs 100% [7.9] , P < 0.05), but not 7 (107% [13.1] vs 100% [7.9] , P > 0.05) and 14 (92.4% [14.7] vs 100% [7.9] , P > 0.05) days after injection. CFA injection-induced pain did not increase IL-6 levels in mice hippocampus at 3, 7, and 14 days after (Fig. 3 , C and D). These data suggest that CFA injection-induced pain might cause a transient increase in IL-6 levels in mouse brain tissues. Moreover, CFA injection-induced pain specifically increased IL-6 levels in cortexes but not in hippocampus, which was consistent with the behavioral findings that CFA injection-induced pain selectively impaired hippocampusindependent learning and memory function.
CFA Injection-Induced Pain Caused a Transient Decrease in Postsynaptic Density 95 Levels in the Cortex, But Not Hippocampus, of Mice Postsynaptic marker PSD-95 has been shown to be associated with synapse number or synaptic loss. A previous study has shown that anesthetic-induced reduction in PSD-95 levels can be inhibited by IL-6 antibody in mouse primary neurons. 16 Given that CFA injection-induced pain increased IL-6 levels in the cortexes of mice, we then asked whether CFA injection-induced pain could reduce PSD-95 levels in brain tissues. PSD-95 immunoblotting showed that CFA injection-induced pain led to a visible reduction in the levels of bands representing PSD-95 in cortexes at 3, but not 7 and 14 days after injection (Fig. 4A ). There was no significant difference in β-Actin levels between the control and pain condition in mice (Fig. 4A ). Western blot quantification was based on the ratio of PSD-95 to β-Actin. One-way ANOVA showed that there was a significant difference in the PSD-95 levels of cortexes after the control condition and pain condition at 3, 7, and 14 days after injection (Fig. 4B , F = 24.19, P < 0.0001). Post hoc test showed that CFA injection-induced pain decreased PSD-95 levels in the cortexes as compared with the control condition at 3 days after injection: 40% Figure 3 . Complete Freund's adjuvant (CFA) injection-induced pain increased IL-6 levels in the cortexes of mice. A, Complete Freund's adjuvant (CFA) injection increased interleukin (IL)-6 levels in cortexes as compared with control condition in Western blot analysis at 3, but not 7 and 14, days after injection. There was no significant difference in the amounts of β-Actin in the cortexes after CFA injection or the control condition. B, Western blot quantification shows that CFA injection increased IL-6 levels in the cortexes as compared with the control condition at 3, but not 7 and 14, days after injection. C, CFA injection did not increase IL-6 levels in the hippocampus as compared with control condition in Western blot analysis at 3, 7, and 14 days after injection. There was no significant difference in the amounts of β-Actin in the hippocampus after CFA injection or the control condition. D, Western blot quantification shows that CFA injection did not increase IL-6 levels in the hippocampus as compared with the control condition at 3, 7, and 14 days after injection. N = 9.
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ANesthesiA & ANAlgesiA [20.4] , P > 0.05) after injection. CFA injection-induced pain in the mice did not decrease PSD-95 levels in hippocampus at 3, 7, and 14 days after injection (Fig. 4, C and D) . These data suggested that CFA injection-induced pain might cause a transient decrease in the synapse number in mouse brain tissues. Moreover, CFA injection-induced pain could specifically decrease synapse number in cortexes but not in mice hippocampus, which was consistent with the findings that CFA injection-induced pain selectively increased IL-6 levels in cortexes (but not mice hippocampus) and impaired the hippocampus-independent learning and memory function.
CFA Injection-Induced Pain Caused Neither Cognitive Impairment Nor Reduction in PSD-95 Levels in IL-6 KO Mice
Given that CFA injection-induced pain in mice increased IL-6 levels, decreased PSD-95 levels in the cortexes of mice, and caused cognitive impairment, we next asked whether the effects of CFA injection-induced pain on brain PSD-95 levels as well as learning and memory function were dependent on IL-6. We used IL-6 KO mice in the studies and found that CFA injection reduced the pain threshold in IL-6 KO mice at 3 (0.032 [0.02] vs 0.851 [0.24] g, P = 0.0001) and 7 (0.340 [0.33] vs 0.983 [0.21] g, P = 0.003) but not 14 (0.913 [0.20] vs 1.04 [0.08] g, P = 0.200) days after injection ( Fig. 5,  A, B , and C). We then found that CFA injection-induced pain did not reduce PSD-95 levels in cortexes at 3 days after injection (Fig. 5, D and E) . Finally, we found that CFA injection-induced pain did not reduce freezing time in the FCS tone and context test at 3 days after injection (Fig. 5, F and  G) . These results demonstrated that the decreases in PSD-95 levels in cortexes and impairment of learning and memory resulting from CFA injection-induced pain might be dependent on elevation of IL-6 levels. Collectively, these findings suggested that CFA injection-induced pain increased IL-6 levels in cortexes, but not hippocampus, that reduced PSD-95 levels in cortexes, but not hippocampus, leading to hippocampus-independent, but not hippocampus-dependent, cognitive impairment.
DISCUSSION
Clinical studies have suggested that pain may be associated with cognitive impairment in humans; 2-8 however, assessing the effects of pain on cognitive function and the There was no significant difference in the amount of β-Actin in the cortexes after CFA injection or the control condition. B, Western blot quantification shows that CFA injection decreased PSD-95 levels in the cortexes as compared with the control condition at 3, but not 7 and 14, days after injection. C, CFA injection did not decrease PSD-95 levels in the hippocampus as compared with the control condition in Western blot analysis at 3, 7, and 14 days after injection. There was no significant difference in the amount of β-Actin in the hippocampus after CFA injection or the control condition. D, Western blot quantification shows that CFA injection did not decrease PSD-95 levels in the hippocampus as compared with the control condition at 3, 7 and 14 days after injection. N = 9.
underlying mechanisms remain largely undetermined. We therefore established a preclinical model in mice to determine the effects of CFA injection-induced pain on learning and memory function and the levels of IL-6 and PSD-95.
We first demonstrated that the CFA injection in the hindpaw of mice caused pain at 3, 7, and 14 days after injection, although the difference did not reach significant levels at 14 days after injection (Fig. 1) . We then were able to show that CFA injection-induced pain caused a transient impairment of learning and memory in mice at 3, but not 7 and 14, days after injection (Fig. 2) .
FCS is among the most commonly used behavioral tests to detect cognitive impairment. 14, 30, 31, [33] [34] [35] The FCS context and tone test can be used to assess hippocampus-dependent and hippocampus-independent learning and memory function. [23] [24] [25] [26] In the present experiments, CFA injection-induced pain only reduced freezing time in the FCS tone test but not the context test (Fig. 2) . These findings suggest that CFA injection-induced pain might selectively cause hippocampus-independent cognitive impairment. Radial maze and specific paradigms of contextual fear conditioning are traditional learning tasks used to assess hippocampus-dependent cognitive function. [36] [37] [38] These behavioral tasks are not available to us at the present time. However, we may develop these tasks to further prove that CFA injection-induced pain can selectively cause hippocampus-independent cognitive impairment in our future studies.
CFA injection-induced pain also increased IL-6 levels and reduced PSD-95 levels in the cortexes of the mice (Fig. 3  and 4 ). Both IL-6 elevation and PSD-95 reduction are associated with cognitive impairment. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] 36, 37 Therefore, these results suggested that CFA injection-induced pain might likely cause cognitive impairment through the elevation of IL-6 levels and the reduction of PSD-95 levels. It is interesting to note that CFA injection-induced pain only increased IL-6 levels and decreased PSD-95 levels in cortexes but not hippocampus. CFA injection-induced pain also selectively caused hippocampus-independent, but not hippocampusdependent, cognitive impairment. These results suggest that there may be associations between CFA-induced pain, There was no significant difference in the amount of β-Actin in the cortexes after CFA injection or the control condition in IL-6 KO mice. G, Western blot quantification shows that CFA injection did not decrease PSD-95 levels in the cortexes as compared with the control condition at 3 days after injection in IL-6 KO mice. N = 9 for the biochemistry studies, N = 10 for the behavioral studies.
ANesthesiA & ANAlgesiA changes in brain IL-6 and PSD-95 levels, and cognitive function. Moreover, CFA injection-induced pain might cause cognitive impairment in mice through an IL-6-dependent and PSD-95-associated mechanism. However, other mechanisms, for example, CFA-induced neuroinflammation, may also be involved in these changes, which need to be investigated further.
CFA injection in IL-6 KO mice caused neither cognitive impairment nor reduction of PSD-95 levels at 3 days after injection (Fig. 5) . These data showed that the effects of CFA injection-induced pain on PSD-95 and cognitive function were dependent on the elevation of IL-6, and further suggested that the CFA injection-induced pain might lead to cognitive impairment via elevation of IL-6 and reduction of PSD-95 in the brain. It is also possible that inflammatory pain and cognitive impairment after CFA injection may not go through the same set of inflammatory cytokines because IL-6 KO mice still have pain but without cognitive impairment.
Elevation of proinflammatory cytokine IL-6 is part of neuroinflammation, and neuroinflammation may cause cognitive dysfunction (reviewed in 9 ). IL-6 has been suggested to contribute to cognitive dysfunction and mild cognitive impairment in medical and surgical patients. 10 In animal studies, IL-6 has also been shown to cause cognitive impairment in rodents. [11] [12] [13] [14] [15] [16] IL-6 has been reported to contribute to neuropathic pain development. Specifically, intrathecal infusion of IL-6 induces mechanoallodynia in nerve-intact mice and thermal hyperalgesia in nerve-injured rats. 38 KO of IL-6 may contribute to the development of tight ligation and transection of L5 spinal nerve-induced mechanoallodynia but not thermal allodynia in mice. 27 The current studies have found that IL-6 may be involved in neuroinflammatory pain-induced cognitive impairment. Moreover, our recent study has shown that surgical incision-induced pain may cause cognitive impairment via reduction of the synaptic N-methyl-d-aspartate receptor 2B. 39 Taken together, these data suggest the association of pain, neuroinflammation, synaptic function, and cognitive function. It is therefore important to further investigate the role of IL-6 in pain, neuroinflammation, synaptic function, and cognitive impairment and elucidate the underlying mechanisms. Such studies would facilitate future mechanistic investigation of pain-associated cognitive impairment.
CFA injection-induced pain lasted at least 7 days after injection. However, the injection of CFA-induced hippocampus-independent cognitive impairment and changes in IL-6 and PSD-95 levels in the cortex at 3, but not 7 and 14, days after injection ( Figs. 3 and 4) . The exact reason underlying these findings is unknown. However, these findings suggest that there could be some tolerance effects after CFA injection-induced pain, which would limit the duration of pain-induced cognitive impairment. Further studies to test this hypothesis are warranted.
It is unclear why CFA injection-induced pain only increased IL-6 levels and reduced PSD-95 levels in the cortex, but not hippocampus, and caused hippocampus-independent cognitive impairment. A previous study has also shown that sleep disturbance selectively induces neuroinflammation in hippocampus and hippocampus-dependent cognitive impairment in mice. 14 Therefore, it is conceivable that different physical stimulation or disturbance may affect different brain regions and the associated behavioral changes. Moreover, a recent study demonstrated that pain could induce a neural "signature," a brain-wide pattern of excitation and inhibition, in specific brain regions, for example, cortex. 40 The findings from our current studies suggest that CFA injection-induced pain in mice may induce a brain region-specific change in neuroinflammation, synapse number, and neurobehavioral deficits.
A study by Shu et al. 41 has shown that injection of formalin in the hindpaw of mice induced neurotoxicity, for example, increases in the levels of caspase-3 positive cells in brain tissues, which is consistent with our current findings that injection of CFA in the hindpaw increased IL-6 levels and reduced PSD-95 levels. Chemically induced pain may not cause long-term cognitive impairment because the injection of formalin 41 or CFA (the findings from the current study) did not cause cognitive impairment at 14 and 7 days after injection, respectively. It is interesting to note that injection of formalin did not increase the levels of tumor necrosis factor-α and IL-1β, but the injection of CFA increased IL-6 levels in brain tissues of mice. The underlying mechanisms of this difference need further investigation.
Lunardi et al. 42 reported that anesthetics (nitrous oxide and isoflurane) can impair synaptogenesis, including the reduction in synapse number and disturbances in ultrastructural properties of developing synapses in young rats. These data suggest that anesthetics may induce cognitive impairment in young rodents via impairment of synaptogenesis. Our current studies showed that pain might also affect synapse function, for example, reduction in PSD-95 levels. Anesthetics have been shown to enhance pain-induced neurotoxicity (e.g., caspase-3 activation). 41 Therefore, it is conceivable that anesthetics may also enhance pain-induced synapse dysfunction, for example, reduction in PSD-95 levels, leading to increased cognitive impairment. Future studies to determine whether pain and anesthetics can enhance each other's effects in causing synapse dysfunction and cognitive impairment are warranted.
Our study has several limitations. First, we only assessed the effects of CFA injection-induced pain on IL-6 and PSD-95 levels in the hippocampus and cortex. Future studies should determine whether CFA injection-induced pain could also increase IL-6 levels and reduce PSD-95 levels in other brain regions, for example, the amygdala. Nevertheless, the current findings suggest that CFA injection-induced pain increased IL-6 levels in the cortex, but not hippocampus of mice that then reduced PSD-95 levels in the cortex, leading to hippocampus-independent cognitive impairment (Figs 2, 3 and 4 ). Second, we did not assess whether analgesia, for example, eutectic mixture of lidocaine and prilocaine cream (2.5% lidocaine and 2.5% prilocaine), could rescue the changes in IL-6, PSD-95, and cognitive function after CFA injection-induced pain. This was mainly because eutectic mixture of lidocaine and prilocaine cream might not be effective in treating CFA injection-induced pain, because of the inflammatory tissues. Moreover, we did not want pain medicine, for example, morphine, to influence CFA injection-induced neuroinflammation, reduction in synapse number, and neurobehavioral deficits. The injection of CFA has been well shown to induce pain in rodents. [43] [44] [45] Therefore, the current findings that CFA injection-induced cognitive impairment increased IL-6 levels and reduced PSD-95 levels support our hypothesis that chemically induced pain can induce neuroinflammation, reduction in synapse number, and neurobehavioral deficits.
In conclusion, in this proof of concept study, we established a preclinical model of pain in mice and found that the injection of CFA could cause pain. CFA injectioninduced pain might increase proinflammatory cytokine IL-6 levels and decrease PSD-95 levels in cortexes but not in hippocampus. CFA injection-induced pain also impaired hippocampus-independent learning and memory. Finally, KO of IL-6 (in IL-6 KO mice) prevented the effects of CFA injection-induced pain on PSD-95 levels and cognitive impairment. These findings should encourage studies further, studies to determine the role of pain in cognitive function decline. Any new studies should include assessment of underlying mechanism(s) by which chemically induced pain induces brain region-specific neuroinflammation and reduction in synapse number, and the associated neurobehavioral deficits. E
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